Posts

Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses – key facts and context

on

Eli Lilly partners with Oura to support GLP-1 patients via smart‑ring tools

on

Eli Lilly Invests Additional $4.5B in Indiana Manufacturing Facilities at LEAP District

on

Lilly's Retatrutide Achieves 16.8% Weight Loss and A1C Reductions in Phase 3 Diabetes Trial, Comparable to Mounjaro

on

Eli Lilly Beats Sales Forecasts and Targets Major 2026 Growth, Outpacing Novo Nordisk

on

Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Valuation

on

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

on

Lilly's Mounjaro Shows Strong Results in Youth Type 2 Diabetes, Paving Way for Expansion

on

Stockpiling Frenzy Prompts Lilly to Suspend UK Mounjaro Supply

on

Eli Lilly Endorses Trump's Goal by Raising Drug Prices Abroad to Align with U.S. Levels

on

Eli Lilly Vows Vigorous Defense as Texas Sues Over Alleged Drug Kickbacks

on

Lilly's Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval

on

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

on

Compounders just lost their case to put obesity drug tirzepatide back in shortage

on

Eli Lilly's Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall

on